Literature DB >> 1594618

Chimpanzees immunized with recombinant soluble CD4 develop anti-self CD4 antibody responses with anti-human immunodeficiency virus activity.

M Watanabe1, J E Boyson, C I Lord, N L Letvin.   

Abstract

In view of the efficiency with which human immunodeficiency virus replication can be blocked in vitro with anti-CD4 antibodies, the elicitation of an anti-CD4 antibody response through active immunization might represent a useful therapeutic strategy for AIDS. Here we demonstrate that immunization of chimpanzees with recombinant soluble human CD4 elicited an anti-CD4 antibody response. The elicited antibody bound self CD4 on digitonin-treated but not freshly isolated lymphocytes. Nevertheless, this antibody blocked human immunodeficiency virus replication in chimpanzee and human lymphocytes. These observations suggest that immunization with recombinant soluble CD4 from human immunodeficiency virus-infected humans may be feasible and therapeutically beneficial.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1594618      PMCID： PMC49237          DOI： 10.1073/pnas.89.11.5103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  13 in total

1.  HIV infection is blocked in vitro by recombinant soluble CD4.

Authors:  R A Fisher; J M Bertonis; W Meier; V A Johnson; D S Costopoulos; T Liu; R Tizard; B D Walker; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response.

Authors:  M Watanabe; C G Levine; L Shen; R A Fisher; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

3.  A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease.

Authors:  M Watanabe; D J Ringler; P N Fultz; J J MacKey; J E Boyson; C G Levine; N L Letvin
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Monoclonal antibodies reactive with the T cell receptor zeta chain: production and characterization using a new method.

Authors:  P Anderson; M L Blue; C O'Brien; S F Schlossman
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

5.  Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques.

Authors:  M Watanabe; K A Reimann; P A DeLong; T Liu; R A Fisher; N L Letvin
Journal:  Nature       Date:  1989-01-19       Impact factor: 49.962

6.  Immunization with soluble murine CD4 induces an anti-self antibody response without causing impairment of immune function.

Authors:  D R Cassatt; R W Sweet; J A Arthos; A Truneh
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

7.  Regions of the CD4 molecule not involved in virus binding or syncytia formation are required for HIV-1 infection of lymphocytes.

Authors:  T Hasunuma; H Tsubota; M Watanabe; Z W Chen; C I Lord; L C Burkly; J F Daley; N L Letvin
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

8.  Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication.

Authors:  M Watanabe; Z W Chen; H Tsubota; C I Lord; C G Levine; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

9.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

10.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.

Authors:  R T Schooley; T C Merigan; P Gaut; M S Hirsch; M Holodniy; T Flynn; S Liu; R E Byington; S Henochowicz; E Gubish
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391
View more
  7 in total

1.  Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis.

Authors:  Y Yonamine; M Watanabe; F Kinjo; T Hibi
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

2.  An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Authors:  Jennifer A Schwartz; Ilia Prado; Johnathan Misamore; Deborah Weiss; Jesse Francis; Ranajit Pal; Maria Huaman; Anthony Cristillo; George K Lewis; Robert C Gallo; Anthony L DeVico; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

Review 3.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

4.  Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.

Authors:  L Burkly; N Mulrey; R Blumenthal; D S Dimitrov
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

5.  Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.

Authors:  P Lanza; R Billetta; S Antonenko; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

6.  CD4 and its role in infection of rabbit cell lines by human immunodeficiency virus type 1.

Authors:  B F Hague; S Sawasdikosol; T J Brown; K Lee; D P Recker; T J Kindt
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

7.  A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4.

Authors:  R E Bachelder; J Bilancieri; W Lin; N L Letvin
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.